Serum Adiponectin as an Early Marker for Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease.

Assiut University

Status: Unknown

Conditions: Non-Alcoholic Fatty Liver Disease

Treatments: Diagnostic Test: serum Adiponectin

Study type: Observational

Funder types: Other

Identifiers

NCT05106049

Adiponectin in NAFLD

Details and patient eligibility

About

Early detection of renal impairment in patients with non-alcoholic fatty liver disease and its correlation with serum Adiponectin level.

Full description

Detection of serum Adiponectin by ELISA technique using (EIA-3418) KIT, DRG international inc., USA

Enrollment: 90 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with fatty liver aged from 18 to 60 yrs either diabetic or not .
• Patient with normal echogenic kidney in ultrasound and eGFR more than 60 mL/min/1.73m2.
• The Control group are completely healthy subjects without any systemic or liver and kidney affection

Exclusion criteria

• Patients less than 18 yrs & more than 60 yrs .
• All patients having any other causes of renal and hepatic disease rather than Diabetes and having any other systemic problem.

Trial design

90 participants in 2 patient groups

cases

Description:

non-alcoholic fatty liver patients

Treatment:

Diagnostic Test: serum Adiponectin

control

Description:

healthy persons

Treatment:

Diagnostic Test: serum Adiponectin